Tobias Heintges

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Medicine, Oncology, Pharmacology +9

Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B

Claus Niederau, Tobias Heintges, Stefan Lange et al. · New England Journal of Medicine · 1996 · 812 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C

Karen L. Lindsay, Christian Trépo, Tobias Heintges et al. · Hepatology · 2001 · 665 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Prognosis of Chronic Hepatitis C: Results of A Large, Prospective Cohort Study

Claus Niederau, Stefan Lange, Tobias Heintges et al. · Hepatology · 1998 · 638 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +17

Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin

Thomas Berg, Michael Wagner, Samer Nasser et al. · Gastroenterology · 2006 · 519 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16